N. Thatcher
The Christie Hospital · 227 works · 8,818 citations · h-index 46
Top works
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer
- Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
- Improving quality of life in patients with non-small cell lung cancer: Research experience with gemcitabine
- Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
- Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients
- Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
- Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
- In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
- Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens